Combined Metabolic Activators (CMA) Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease 2021

[Bolt_Upright]

These are the same people that did the Alzheimer's trial  PDWarrior1900 wrote about: 29% IMPROVEMENT in Alzheimer's using just 4 supplements in Phase 2 Clinical Study healthunlocked.com/cure-par...

I started a new thread so people would see this is for PD too:

Combined Metabolic Activators (CMA) Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease 2021 medrxiv.org/content/10.1101...

"Here, we designed a randomized, double-blinded, placebo-controlled, phase-2 study in PD patients with CMA administration. We found that the cognitive functions in PD patients is significantly improved 21% in the CMA group, whereas it is improved only 11% in the placebo group after 84 days of CMA administration. We also found that the administration of CMA did not affect motor functions in PD patients. We performed a comprehensive multi-omics analysis of plasma proteins and metabolites, and revealed the molecular mechanism associated with the treatment of the patients. In conclusion, our results show that treating PD patients with CMAs leads to enhanced cognitive function, as recently reported in AD patient."

More details on this other page: aboutnad.com/scientific-ana...

(Dosage looks the same as the AD trial)

"The study was a randomized, double-blinded, placebo-controlled phase II clinical study of mild-to-moderate PD patients who were between 41-84 years of age. Majority of the patients were male. Each dose consisted of 3.73g L-carnitine tartrate, 1g NR, 12.35g serine, and 2.55g (NAC). All patients received one dose of CMA twice per day [3].

Researchers found that CMA supplementation significantly improved cognitive function by 21% in patients with PD, compared to 11% in the placebo group after 84 days. The improvement in cognitive function was more dramatic in more severe PD patients. Although an improvement in cognitive function was observed, CMA supplementation did not alter the patients’ motor scores [3].

CMAs also significantly improved levels of serum aspartate aminotransferase (AST, a marker of liver damage), total bilirubin, high-density lipoprotein (HDL, or “good” cholesterol), and triglycerides [3]."

[chartist]

Bolt,

I just got done reading this study for CMA use for PD and it seems odd to me that they used the Montreal Cognitive Assessment(MoCA) instead of the newer MDS UPDRS for PD. The MoCA seems appropriate for dementia or AD, but the MDS UPDRS would have been a much better choice for PD because it covers many more things very relevant to PD in greater detail than previously. They did use UPDRS 111 testing to determine that CMA did not improve motor symptoms though.

I also noticed that they spoke at length about the biological effects caused by CMA, but did not discuss any actual effects in the study participants. Based on what they said, CMA, based on MoCA scoring clearly had more impact in the other study than this study. I also notice they divided the study groups into higher and lower MoCA scoring groups in both studies.

I was confused by the following statements in this study :

' 5 patients dropped out of the study before Day 84 visit during the COVID-19 lockdown. On days 0, 28 and 84, we assessed the clinical variables and analyzed the differences between day 0 and day 28 as well as day 0 and day 84 in the CMA and placebo groups (Dataset S2). '

They did not say what groups the 5 dropouts came from and they implied that it was due to Covid-19 lockdown, but didn't clarify if that was the reason or something else.

In the next paragraph they said 5 people in the CMA group reported "mild adverse events", but did not clarify what those mild adverse events were.

Overall, they gave a lot of detail, but not the details I would have expected for a self described PD study.

Art

[Bolt_Upright in reply to chartist]

Good review. The way I look at it (High School education) is it seems they did the exact same trial on AD and PD so I would expect the same biological effects (good effects).

I wish the PD trial data included the before and after motor functions. Saying motor functions did not improve is one thing, saying they did not get worse either (which they did not say) would be pretty darn good too.

[chartist in reply to Bolt_Upright]

Yes, I felt like they were a little light on the details that would matter in PD.

Art